14 results
10-Q
2022 Q3
PRME
Prime Medicine Inc
14 Nov 22
Quarterly report
4:46pm
of the COVID-19 pandemic, and the ability to raise additional capital to fund operations. The Company’s product candidates currently under … with the Securities and Exchange Commission (the “SEC”) on October 21, 2022.
Impact of the COVID-19 Pandemic
The Company is subject to a number of risks
424B4
PRME
Prime Medicine Inc
21 Oct 22
Prospectus supplement with pricing info
4:47pm
and clinical trials for any product candidates we may identify;
experience any delays or interruptions due to the ongoing COVID-19 pandemic, including … widespread outbreaks of contagious disease, including the ongoing COVID-19 pandemic, which could significantly disrupt our operations, impact our financial
S-1/A
mrf8h uu37fvkr5jgpkc
13 Oct 22
IPO registration (amended)
10:51am
S-1
35rhtcf
23 Sep 22
IPO registration
4:12pm
DRS/A
lwsxxed8
5 Aug 22
Draft registration statement (amended)
12:00am
DRS/A
wihxt
6 May 22
Draft registration statement (amended)
12:00am
DRS/A
k5x8nwnfhbv5 pk92c6i
8 Apr 22
Draft registration statement (amended)
12:00am
DRS/A
4e6 u9qawy05
25 Mar 22
Draft registration statement (amended)
12:00am
DRS/A
ny9do7k rewv9x7s58s
7 Mar 22
Draft registration statement (amended)
12:00am
DRS/A
dkchmdajki2g7 m5r3
4 Feb 22
Draft registration statement (amended)
12:00am
DRS
oli3iteqv1w6o9iiqf
20 Dec 21
Draft registration statement
12:00am
- Prev
- 1
- Next